Guerra, C. et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 19, 728–739 (2011).

CAS  PubMed  PubMed Central  Google Scholar 

Lee, J. W., Komar, C. A., Bengsch, F., Graham, K. & Beatty, G. L. Genetically engineered mouse models of pancreatic cancer: the KPC model (LSL-Kras(G12D/+);LSL-Trp53(R172H/+);Pdx-1-Cre), its variants, and their application in immuno-oncology drug discovery. Curr. Protoc. Pharmacol. 73, 14.39.11–14.39.20 (2016).

Google Scholar 

Kruger, D., Yako, Y. Y., Devar, J., Lahoud, N. & Smith, M. Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: enhancing diagnostic accuracy. PLoS ONE 14, e0221169 (2019).

CAS  PubMed  PubMed Central  Google Scholar 

Cassetta, L. et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell 35, 588.e10–602.e10 (2019).

Google Scholar 

Hu, H., Jiao, F., Han, T. & Wang, L. W. Functional significance of macrophages in pancreatic cancer biology. Tumour Biol. 36, 9119–9126 (2015).

CAS  PubMed  PubMed Central  Google Scholar 

Cassetta, L. & Kitamura, T. Targeting tumor-associated macrophages as a potential strategy to enhance the response to immune checkpoint inhibitors. Front. Cell Dev. Biol. 6, 38 (2018).

PubMed  PubMed Central  Google Scholar 

Mace, T. A. et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut 67, 320–332 (2018).

CAS  PubMed  Google Scholar 

McClanahan, F. et al. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Emicro-TCL1 CLL mouse model. Blood 126, 212–221 (2015).

CAS  PubMed  PubMed Central  Google Scholar 

Nomi, T. et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 13, 2151–2157 (2007).

CAS  PubMed  Google Scholar 

O’Reilly, E. M. et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 5, 1431–1438 (2019).

PubMed Central  Google Scholar 

Ozdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719–734 (2014).

CAS  PubMed  PubMed Central  Google Scholar 

Bolm, L. et al. The role of fibroblasts in pancreatic cancer: extracellular matrix versus paracrine factors. Transl. Oncol. 10, 578–588 (2017).

PubMed  PubMed Central  Google Scholar 

Wei, L. et al. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. Cell Death Dis. 9, 1065 (2018).

PubMed  PubMed Central  Google Scholar 

Dewys, W. D. et al. Prognostic effect of weight loss prior tochemotherapy in cancer patients. Am. J. Med. 69, 491–497 (1980).

CAS  PubMed  Google Scholar 

Fearon, K. C. The Sir David Cuthbertson Medal Lecture 1991. The mechanisms and treatment of weight loss in cancer. Proc. Nutr. Soc. 51, 251–265 (1992).

CAS  PubMed  Google Scholar 

Bachmann, J. et al. Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function. BMC Cancer 9, 255 (2009).

PubMed  PubMed Central  Google Scholar 

Gordon, J. N. et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54, 540–545 (2005).

CAS  PubMed  PubMed Central  Google Scholar 

Tsoli, M. et al. Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. Cancer Res. 72, 4372–4382 (2012).

CAS  PubMed  Google Scholar 

Das, S. K. et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 333, 233–238 (2011).

ADS  CAS  PubMed  Google Scholar 

Arner, P., Bolinder, J., Engfeldt, P. & Ostman, J. The antilipolytic effect of insulin in human adipose tissue in obesity, diabetes mellitus, hyperinsulinemia, and starvation. Metabolism 30, 753–760 (1981).

CAS  PubMed  Google Scholar 

Petruzzelli, M. et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20, 433–447 (2014).

CAS  PubMed  Google Scholar 

Cahlin, C. et al. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res. 60, 5488–5493 (2000).

CAS  PubMed  Google Scholar 

Pestka, S. et al. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol. 22, 929–979 (2004).

CAS  PubMed  Google Scholar 

Blumberg, H. et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 104, 9–19 (2001).

CAS  PubMed  Google Scholar 

Dumoutier, L., Leemans, C., Lejeune, D., Kotenko, S. V. & Renauld, J. C. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J. Immunol. 167, 3545–3549 (2001).

CAS  PubMed  Google Scholar 

Kragstrup, T. W. et al. Increased interleukin (IL)-20 and IL-24 target osteoblasts and synovial monocytes in spondyloarthritis. Clin. Exp. Immunol. 189, 342–351 (2017).

CAS  PubMed  PubMed Central  Google Scholar 

Chiu, Y. S. et al. Anti-IL-20 monoclonal antibody inhibited tumor growth in hepatocellular carcinoma. Sci. Rep. 7, 17609 (2017).

ADS  PubMed  PubMed Central  Google Scholar 

Hsu, Y. H. et al. Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine models. J. Immunol. 188, 1981–1991 (2012).

CAS  PubMed  Google Scholar 

Hsu, Y. H. et al. Anti-IL-20 monoclonal antibody suppresses prostate cancer growth and bone osteolysis in murine models. PLoS ONE 10, e0139871 (2015).

PubMed  PubMed Central  Google Scholar 

Hsu, Y. H., Wei, C. C., Shieh, D. B., Chan, C. H. & Chang, M. S. Anti-IL-20 monoclonal antibody alleviates inflammation in oral cancer and suppresses tumor growth. Mol. Cancer Res. 10, 1430–1439 (2012).

CAS  PubMed  Google Scholar 

Sa, S. M. et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J. Immunol. 178, 2229–2240 (2007).

CAS  PubMed  Google Scholar 

Hsu, Y. H. et al. Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum. 54, 2722–2733 (2006).

CAS  PubMed  Google Scholar 

Chen, W. Y., Cheng, B. C., Jiang, M. J., Hsieh, M. Y. & Chang, M. S. IL-20 is expressed in atherosclerosis plaques and promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 26, 2090–2095 (2006).

CAS  PubMed  Google Scholar 

Li, H. H. et al. Interleukin-20 induced cell death in renal epithelial cells and was associated with acute renal failure. Genes Immun. 9, 395–404 (2008).

CAS  PubMed  Google Scholar 

Chen, W. Y. & Chang, M. S. IL-20 is regulated by hypoxia-inducible factor and up-regulated after experimental ischemic stroke. J. Immunol. 182, 5003–5012 (2009).

CAS  PubMed  Google Scholar 

Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469–483 (2005).

CAS  PubMed  Google Scholar 

Wang, Y. et al. PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma. Med. Oncol. 32, 212 (2015).

PubMed  Google Scholar 

Alsuliman, A. et al. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol. Cancer 14, 149 (2015).

PubMed  PubMed Central  Google Scholar 

Chiu, Y. S., Wei, C. C., Lin, Y. J., Hsu, Y. H. & Chang, M. S. IL-20 and IL-20R1 antibodies protect against liver fibrosis. Hepatology 60, 1003–1014 (2014).

CAS  PubMed  Google Scholar 

Eppihimer, M. J. et al. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 9, 133–145 (2002).

CAS  PubMed  PubMed Central  Google Scholar 

Daley, D. et al. NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma. J. Exp. Med. 214, 1711–1724 (2017).

CAS  PubMed  PubMed Central  Google Scholar 

Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).

CAS  PubMed  PubMed Central  Google Scholar 

Acharyya, S. et al. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 8, 421–432 (2005).

CAS  PubMed  Google Scholar 

Legaspi, A., Jeevanandam, M., Starnes, H. F. Jr. & Brennan, M. F. Whole body lipid and energy metabolism in the cancer patient. Metabolism 36, 958–963 (1987).

CAS  PubMed  Google Scholar 

Kir, S. et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature 513, 100–104 (2014).

ADS  CAS  PubMed  PubMed Central  Google Scholar 

Agustsson, T. et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res. 67, 5531–5537 (2007).

CAS  PubMed  Google Scholar 

Yang, X., Zhang, X., Heckmann, B. L., Lu, X. & Liu, J. Relative contribution of adipose triglyceride lipase and hormone-sensitive lipase to tumor necrosis factor-α (TNF-α)-induced lipolysis in adipocytes. J. Biol. Chem. 286, 40477–40485 (2011).

CAS  PubMed  PubMed Central  Google Scholar 

Tisdale, M. J. Mechanisms of cancer cachexia. Physiol. Rev. 89, 381–410 (2009).

CAS  PubMed  Google Scholar 

Long, K. B., Collier, A. I. & Beatty, G. L. Macrophages: key orchestrators of a tumor microenvironment defined by therapeutic resistance. Mol. Immunol. 110, 3–12 (2019).

CAS  PubMed  Google Scholar 

Beatty, G. L. et al. Exclusion of T cells from pancreatic carcinomas in mice is regulated by Ly6C(low) F4/80(+) extratumoral macrophages. Gastroenterology 149, 201–210 (2015).

CAS  PubMed  PubMed Central  Google Scholar 

Löhr, M. et al. Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res. 61, 550–555 (2001).

PubMed  Google Scholar 

Anggorowati, N. et al. Histochemical and immunohistochemical study of α-SMA, collagen, and PCNA in epithelial ovarian neoplasm. Asian Pac. J. Cancer Prev. 18, 667–671 (2017).

PubMed  PubMed Central  Google Scholar 

Yao, H. et al. Role of α(5)β(1) integrin up-regulation in radiation-induced invasion by human pancreatic cancer cells. Transl. Oncol. 4, 282–292 (2011).

PubMed  PubMed Central  Google Scholar 

Rice, A. J. et al. Matrix stiffness induces epithelial-mesenchymal transition and promotes chemoresistance in pancreatic cancer cells. Oncogenesis 6, e352 (2017).

CAS  PubMed  PubMed Central  Google Scholar 

Liang, Y. et al. Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. Nat. Commun. 9, 4586 (2018).

ADS  PubMed  PubMed Central  Google Scholar 

Le, D. T. et al. Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). J. Clin. Oncol. 33, TPS4148 (2015).

Google Scholar 

Firdaus, I. et al. nab-paclitaxel (nab-P) + nivolumab (Nivo) ± gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC). J. Clin. Oncol. 34, TPS475 (2016).

Google Scholar 

Wainberg, Z. A. et al. Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors. J. Clin. Oncol. 34, TPS465 (2016).

Google Scholar 

Das, S., Shapiro, B., Vucic, E. A., Vogt, S. & Bar-Sagi, D. Tumor cell-derived IL-1β promotes desmoplasia and immune suppression in pancreatic cancer. Cancer Res. 2080, 2019 (2020).

Google Scholar 

Zhu, X. et al. MyD88 signalling is critical in the development of pancreatic cancer cachexia. J. Cachexia Sarcopenia Muscle 10, 378–390 (2019).

PubMed  PubMed Central  Google Scholar 

Zaki, M. H., Nemeth, J. A. & Trikha, M. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int. J. Cancer 111, 592–595 (2004).

CAS  PubMed  Google Scholar 

Zhang, G. et al. Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways. Sci. Rep. 7, 2273–2273 (2017).

ADS  PubMed  PubMed Central  Google Scholar 

Hsieh, M. Y. et al. Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes Immun. 7, 234–242 (2006).

CAS  PubMed  Google Scholar 

Wei, C. C. et al. Detection of IL-20 and its receptors on psoriatic skin. Clin. Immunol. 117, 65–72 (2005).

CAS  PubMed  Google Scholar 

Hsu, Y. H. et al. Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. J. Exp. Med. 208, 1849–1861 (2011).

CAS  PubMed  PubMed Central  Google Scholar 

Ying, W., Cheruku, P. S., Bazer, F. W., Safe, S. H. & Zhou, B. Investigation of macrophage polarization using bone marrow derived macrophages. J. Vis. Exp. 76, e50323 (2013).